Top

09-01-2025 | Kidney Cancer | REVIEW

Paediatric renal tumours: an update on challenges and recent developments

Authors: Gino R. Somers, Aurore L’Herminé-Coulomb, Andres Matoso, Maureen J. O’Sullivan

Abstract

Paediatric renal tumours include a broad range of neoplasms which largely differ, but also overlap to a smaller extent, with adult kidney cancer. These include the embryonal tumour nephroblastoma, which accounts for the majority of cases of kidney cancer in the first decade of life and, despite boasting a cure in ~ 90% cases, still presents clinical challenges in a small proportion of cases. A variety of less common mesenchymal tumours, including the mostly indolent congenital mesoblastic nephroma, clear cell sarcoma of kidney which continues to be associated with poor outcomes for higher stage disease, and the typically lethal malignant rhabdoid tumour, form the bulk of the remaining presentations in the first decade. All three of these represent the intrarenal form of a wider ‘family’ of genetically related and histologically overlapping entities occurring in soft tissue and other anatomical locations. The latter two are examples of aggressive ‘epigenetic’ tumours driven by dysregulation of chromatin. In the second decade of life, renal cell carcinoma dominates, and with molecular characterisation many distinct subtypes are now described. Herein we discuss the developments in relation to diagnostic categorisation of paediatric renal cancers and how deeper understanding of the underlying biology is already providing therapeutic opportunity, while also focussing on the challenges that remain for the pathologist.

Glembocki AI, Somers GR (2024) Prognostic and predictive biomarkers in paediatric solid tumours. Pathology 56:283–296. https://doi.org/10.1016/j.pathol.2023.11.007CrossRefPubMed

Vujanic GM, Chang KTE, Tanaka Y, Tsuzuki T (2022) Nephroblastoma. WHO Classification of Tumours: Paediatric Tumours, 5th edn. International Agency for Research on Cancer, Lyon, France, pp 697–701

Eble JN, Argani P, Grignon DJ, Cheng L (2022) AFIP atlases of tumour and non-tumour pathology: tumours of the kidney, bladder, and related urinary structures, series 5. American Registry of Pathology, Arlington VA, pp 1–34

Breslow N, Olshan A, Beckwith JB, Green DM (1993) Epidemiology of Wilms tumour. Med Pediatr Oncol 21:172–181. https://doi.org/10.1002/mpo.2950210305CrossRefPubMed

Scott RH, Stiller CA, Walker L, Rahman N (2006) Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 43:705–15. https://doi.org/10.1136/jmg.2006.041723CrossRefPubMedPubMedCentral

van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, et al, on behalf of the International Society of Paediatric Oncology — Renal Tumour Study Group (SIOP–RTSG) (2017) Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol. Nat Rev Urol 14:743–752

Dome JS, Perlman EJ, Graf N (2014) Risk stratification for Wilms tumour: current approach and future directions. Am Soc Clin Oncol Educ Book 34:215–23. https://doi.org/10.14694/EdBook_AM.2014.34.215CrossRef

Jackson TJ, Williams RD, Brok J, Chowdhury T, Ronghe M, Powis M, Pritchard-Jones K, Vujanić GM, Children’s Cancer and Leukaemia Group (CCLG) (2019) Renal Tumours Group. The diagnostic accuracy and clinical utility of paediatric renal tumour biopsy: Report of the UK experience in the SIOP UK WT (2001) trial. Pediatr Blood Cancer 66:e27627. https://doi.org/10.1002/pbc.27627CrossRef

Vujanić GM, Parsons LN, D’Hooghe E, Treece AL, Collini P, Perlman EJ (2022) Pathology of Wilms tumour in International Society of Paediatric Oncology (SIOP) and Children’s oncology Group (COG) renal tumour studies: Similarities and differences. Histopathology 80:1026–1037. https://doi.org/10.1111/his.14632CrossRefPubMed

10.

Perlman E, Chang KTE, Coulomb A et al (2023) Paediatric renal tumours histopathology reporting guide, 1st edn. International Collaboration on Cancer Reporting; Sydney, Australia, pp 978-1-922324-40–5

11.

Mrad C, Chamouni A, Guerra X, Tordjman M, Tabone MD, Audry G, Irtan S (2024) Nephrometry scoring systems for nephron sparing surgery in children. J Pediatr Hematol Oncol 46(1):1–7CrossRefPubMed

12.

Davis JL, Treece A, Perlman E, Dome JS, Parsons L (2023) Protocol for the examination of resection specimens from patients with Wilms and other paediatric renal tumours. College of American Pathologists, version 4.3.0.1. Downloaded from: CAP Wilms Protocol Sept 2023

13.

Vujanić GM, D’Hooghe E, Popov SD, Sebire NJ, Kelsey A (2018) The effect of preoperative chemotherapy on histological subtyping and staging of Wilms tumours: the United Kingdom Children’s Cancer Study Group (UKCCSG) Wilms tumour trial 3 (UKW3) experience. Pediatr Blood Cancer 66:e27549. https://doi.org/10.1002/pbc.27549CrossRefPubMed

14.

Ooms AHAG, Vujanić GM, D’Hooghe E et al (2020) Renal tumours of childhood—a histopathologic pattern-based diagnostic approach. Cancers (Basel) 12(3):729CrossRefPubMed

15.

Vujanić GM, Gessler M, Ooms AHAG, et al; International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP–RTSG) (2018) The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol 15(11):693-701 https://doi.org/10.1038/s41585-018-0100-3

16.

Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, Breslow N, Green DM (1996) Focal versus diffuse anaplasia in Wilms tumour - new definitions with prognostic significance: a report from the National Wilms Tumour Study Group. Am J Surg Pathol 20(8):909–920. https://doi.org/10.1097/00000478-199608000-00001CrossRefPubMed

17.

Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J (1994) Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7(1):91–97. https://doi.org/10.1038/ng0594-91CrossRefPubMed

18.

Su X, Lu X, Bazai SK et al (2023) Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumours. Nat Commun 14(1):7884CrossRefPubMedPubMedCentral

19.

Vujanić G, Mifsud W, Chowdhury T, Al-Saadi R, Pritchard-Jones K (2022) Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumours registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002–2020). Cancer 128(8):1666–1675CrossRefPubMed

20.

Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S (2019) The genetic changes of Wilms tumour. Nat Rev Nephrol 15:240–251CrossRefPubMed

21.

Tomlinson GE, Kratz CP (2022) Beckwith-Wiedemann and related overgrowth syndromes. WHO Classification of Tumours: Paediatric Tumours, 5th edn. International Agency for Research on Cancer, Lyon, France, pp 989–990

22.

Cresswell GD, Apps JR, Chagtai T et al (2016) Intra-tumour genetic heterogeneity in Wilms tumour: clonal evolution and clinical implications. EBioMedicine 9:120–129. https://doi.org/10.1016/j.ebiom.2016.05.029CrossRefPubMedPubMedCentral

23.

Mrad C, Coulomb-Lhermine A, Tabone MD, Ulinski T, Audry G, Irtan S (2020) Evaluation of the nephron-sparing surgery formula in Wilms tumours. Pediatr Blood Cancer 67(12):e28661. https://doi.org/10.1002/pbc.28661CrossRefPubMed

24.

Mahamdallie S, Yost S, Poyastro-Pearson E et al (2019) Identification of new Wilms tumour predisposition genes: an exome sequencing study. Lancet Child Adolesc Health 3:322–331CrossRefPubMedPubMedCentral

25.

Jiménez I, Chicard M, Colmet-Daage L et al (2019) Circulating tumour DNA analysis enables molecular characterization of paediatric renal tumours at diagnosis. Int J Cancer 144(1):68–79CrossRefPubMed

26.

Ortiz MV, Ahmed S, Burns M et al (2019) Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumour. JCI Insight 4(15):e127098. https://doi.org/10.1172/jci.insight.127098CrossRefPubMedPubMedCentral

27.

Argani P, Perlman EJ, Breslow NE et al (2000) Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 24:4–18. https://doi.org/10.1097/00000478-200001000-00002CrossRefPubMed

28.

Kidd JM (1970) Exclusion of certain renal neoplasms from the category of Wilms’ tumor (abstract). Am J Pathol 59:16a

29.

Morgan E, Kidd JM (1978) Undifferentiated sarcoma of the kidney: a tumor of childhood with histopathologic and clinical characteristics distinct from Wilms’ tumor. Cancer 42:1916–1921. https://doi.org/10.1002/1097-0142(197810)42:4%3c1916::aid-cncr2820420433%3e3.0.co;2-rCrossRefPubMed

30.

Marsden HB, Lawler W (1978) Bone-metastasizing renal tumour of childhood. Br J Cancer 38:437–441. https://doi.org/10.1038/bjc.1978.226CrossRefPubMedPubMedCentral

31.

Benedetti DJ et al (2024) Treatment and outcomes of clear cell sarcoma of the kidney: a report from the Children’s Oncology Group studies AREN0321 and AREN03B2. Cancer. https://doi.org/10.1002/cncr.35266CrossRefPubMed

32.

Balarezo FS, Joshi VV (2001) Clear cell sarcoma of the pediatric kidney: detailed description and analysis of variant histologic patterns of a tumor with many faces. Adv Anat Pathol 8:98–108. https://doi.org/10.1097/00125480-200103000-00006CrossRefPubMed

33.

Cutcliffe C, Kersey D, Huang C-C, Walterhouse D, Perlman EJ (2005) Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 11(22):7986–7994. https://doi.org/10.1158/1078-0432.CCR-05-1354CrossRefPubMed

34.

Punnett HH, Halligan GE, Zaeri N, Karmazin N (1989) Translocation 10;17 in clear cell sarcoma of the kidney A first report. Cancer Genet Cytogenet 41:123–128. https://doi.org/10.1016/0165-4608(89)90116-7CrossRefPubMed

35.

Rakheja D, Weinberg AG, Tomlinson GE, Partridge K, Schneider NR (2004) Translocation (10;17)(q22;p13): a recurring translocation in clear cell sarcoma of kidney. Cancer Genet Cytogenet 154:175–179. https://doi.org/10.1016/j.cancergencyto.2004.02.024CrossRefPubMed

36.

Brownlee NA et al (2007) Recurring translocation (10;17) and deletion (14q) in clear cell sarcoma of the kidney. Arch Pathol Lab Med 131:446–451. https://doi.org/10.5858/2007-131-446-RTADQICrossRefPubMed

37.

O’Meara E et al (2012) Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol 227:72–80. https://doi.org/10.1002/path.3985CrossRefPubMed

38.

Kenny C et al (2018) Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney. J Pathol 244:334–345. https://doi.org/10.1002/path.5020CrossRefPubMed

39.

Karlsson J et al (2014) Clear cell sarcoma of the kidney demonstrates an embryonic signature indicative of a primitive nephrogenic origin. Genes Chromosomes Cancer 53:381–391. https://doi.org/10.1002/gcc.22149CrossRefPubMedPubMedCentral

40.

Ueno-Yokohata H et al (2015) Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. Nat Genet 47:861–863. https://doi.org/10.1038/ng.3338CrossRefPubMed

41.

Kenny C et al (2016) Mutually exclusive BCOR internal tandem duplications and YWHAE-NUTM2 fusions in clear cell sarcoma of kidney: not the full story. J Pathol 238:617–620. https://doi.org/10.1002/path.4693CrossRefPubMed

42.

Kao Y-C et al (2016) BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities. Am J Surg Pathol 40:1670–1678CrossRefPubMedPubMedCentral

43.

Argani P et al (2018) Diffuse strong BCOR immunoreactivity is a sensitive and specific marker for clear cell sarcoma of the kidney (CCSK) in pediatric renal neoplasia. Am J Surg Pathol 42:1128–1131CrossRefPubMedPubMedCentral

44.

Kenny C et al (2020) Immunophenotype-genotype correlations in clear cell sarcoma of kidney-an evaluation of diagnostic ancillary studies. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 23:345–351. https://doi.org/10.1177/1093526620910658CrossRef

45.

Junco SE, Wang R, Gaipa JC et al (2013) Structure of the polycomb group protein PCGF1 in complex with BCOR reveals basis for binding selectivity of PCGF homologs. Structure 21(4):665–671. https://doi.org/10.1016/j.str.2013.02.013CrossRefPubMedPubMedCentral

46.

Blackledge NP, Klose RJ (2021) Getting under the skin of polycomb-dependent gene regulation. Genes Dev 35(5–6):301–303. https://doi.org/10.1101/gad.348257.121CrossRefPubMedPubMedCentral

47.

Weeks DA, Malott RL, Zuppan C, Mierau GW, Beckwith JB (1991) Primitive pelvic sarcoma resembling clear cell sarcoma of kidney. Ultrastruct Pathol 15:403–408. https://doi.org/10.3109/01913129109016248CrossRefPubMed

48.

Fehr A, Hansson MC, Kindblom L-G, Stenman G (2012) YWHAE-FAM22 gene fusion in clear cell sarcoma of the kidney. J Pathol 227:e5-7. https://doi.org/10.1002/path.4040CrossRefPubMed

49.

Kao Y-C et al (2016) Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy: overlapping genetic features with clear cell sarcoma of kidney. Am J Surg Pathol 40:1009–1020. https://doi.org/10.1097/PAS.0000000000000629CrossRefPubMedPubMedCentral

50.

Antonescu CR, Kao YC, Xu B et al (2020) Undifferentiated round cell sarcoma with BCOR internal tandem duplications (ITD) or YWHAE fusions: a clinicopathologic and molecular study. Mod Pathol 33(9):1669–1677. https://doi.org/10.1038/s41379-020-0557-5CrossRefPubMedPubMedCentral

51.

Bolande RP, Brough AJ, Izant RJ (1967) Congenital mesoblastic nephroma of infancy. A report of eight cases and the relationship to Wilms’ tumor. Pediatrics 40:272–278CrossRefPubMed

52.

Beckwith JB (1974) Mesenchymal renal neoplasms of infancy revisited. J Pediatr Surg 9:803–805. https://doi.org/10.1016/s0022-3468(74)80210-1CrossRefPubMed

53.

Church AJ, Calicchio ML, Nardi V et al (2018) Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol Off J U S Can Acad Pathol Inc 31:463–473

54.

Misove A, Vicha A, Zapotocky M et al (2021) An unusual fusion gene EML4-ALK in a patient with congenital mesoblastic nephroma. Genes Chromosomes Cancer 60:837–840. https://doi.org/10.1002/gcc.22990CrossRefPubMed

55.

Wegert J, Vokuhl C, Collord G et al (2018) Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 9:2378. https://doi.org/10.1038/s41467-018-04650-6CrossRefPubMedPubMedCentral

56.

Weeks DA, Beckwith JB, Mierau GW, Luckey DW (1989) Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms’ Tumor Study Pathology Center. Am J Surg Pathol 13(6):439–58CrossRefPubMed

57.

Biegel JA (1999) Cytogenetics and molecular genetics of childhood brain tumors. Neuro Oncol 1(2):139–151. https://doi.org/10.1093/neuonc/1.2.139CrossRefPubMedPubMedCentral

58.

Schneppenheim R, Frühwald MC, Gesk S et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86:279–284. https://doi.org/10.1016/j.ajhg.2010.01.013CrossRefPubMedPubMedCentral

59.

Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80(4):805–810. https://doi.org/10.1086/513207CrossRefPubMedPubMedCentral

60.

Beckwith JB, Palmer NF (1978) Histopathology and prognosis of Wilms tumors: results from the First National Wilms’ Tumor Study. Cancer 41:1937–1948. https://doi.org/10.1002/1097-0142(197805)41:5%3c1937::aid-cncr2820410538%3e3.0.co;2-uCrossRefPubMed

61.

Haas JE, Palmer NF, Weinberg AG, Beckwith JB (1981) Ultrastructure of malignant rhabdoid tumor of the kidney: a distinctive renal tumor of children. Hum Pathol 12:646–657. https://doi.org/10.1016/s0046-8177(81)80050-0CrossRefPubMed

62.

Versteege I, Sévenet N, Lange J et al (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394(6689):203–206. https://doi.org/10.1038/28212CrossRefPubMed

63.

Wilson BG, Wang X, Shen X et al (2010) Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18(4):316–328. https://doi.org/10.1016/j.ccr.2010.09.006CrossRefPubMedPubMedCentral

64.

Nakayama RT, Pulice JL, Valencia AM et al (2017) SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet 49(11):1613–1623. https://doi.org/10.1038/ng.3958CrossRefPubMedPubMedCentral

65.

Kenny C, O’Meara E, Ulaş M, Hokamp K, O’Sullivan MJ (2021) Global chromatin changes resulting from single-gene inactivation-the role of SMARCB1 in malignant rhabdoid tumor. Cancers (Basel) 13(11):2561. https://doi.org/10.3390/cancers13112561CrossRefPubMed

66.

Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S et al (2023) Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst 115(11):1355–1363. https://doi.org/10.1093/jnci/djad085CrossRefPubMedPubMedCentral

67.

Nakata K, Colombet M, Stiller CA, Pritchard-Jones K, Steliarova-Foucher E (2020) Contributors I- Incidence of childhood renal tumours: an international population-based study. Int J Cancer 147:3313–3327. https://doi.org/10.1002/ijc.33147CrossRefPubMedPubMedCentral

68.

Akhavan A, Richards M, Shnorhavorian M, Goldin A, Gow K, Merguerian PA (2015) Renal cell carcinoma in children, adolescents and young adults: a National Cancer Database study. J Urol 193:1336–1341. https://doi.org/10.1016/j.juro.2014.10.108CrossRefPubMed

69.

Gurruchaga Sotes I, Alves AN, Arregui SV, Santander Lobera C (2021) Response to combination of pembrolizumab and axitinib in hereditary leyomiomatosis and renal cell cancer (HLRCC). Curr Oncol 28:2346–2350. https://doi.org/10.3390/curroncol28040216CrossRefPubMedPubMedCentral

70.

Argani P, Ladanyi M (2006) The evolving story of renal translocation carcinomas. Am J Clin Pathol 126:332–334. https://doi.org/10.1309/EAEJTJGD5J4J3B4FCrossRefPubMed

71.

Argani P, Antonescu CR, Couturier J, Fournet JC, Sciot R, Debiec-Rychter M, Hutchinson B, Reuter VE, Boccon-Gibod L, Timmons C, Hafez N, Ladanyi M (2002) PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol 26:1553–1566. https://doi.org/10.1097/00000478-200212000-00003CrossRefPubMed

72.

Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA, Ladanyi M (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159:179–192. https://doi.org/10.1016/S0002-9440(10)61684-7CrossRefPubMedPubMedCentral

73.

Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, Netto GJ, Antonescu CR (2016) TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am J Surg Pathol 40:723–737. https://doi.org/10.1097/PAS.0000000000000631CrossRefPubMedPubMedCentral

74.

Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B, Jiang SJ, Wang Y, Wang X, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P, Wang JD, Zhou XJ (2012) Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 36:1327–1338. https://doi.org/10.1097/PAS.0b013e31825aafb5CrossRefPubMed

75.

Argani P, Medeiros LJ, Matoso A, Baraban E, Lotan T, Pawel BR, McKenney JK, Mehra R, Falzarano SM, Pallavajjalla A, Lin MT, Patel S, Rawwas J, Bendel AE, Gagan J, Palsgrove DN (2023) “Oncocytoid renal cell carcinomas after neuroblastoma” represent TSC -mutated eosinophilic solid and cystic renal cell carcinomas : association with prior childhood malignancy and multifocality with therapeutic implications. Am J Surg Pathol 47:1335–1348. https://doi.org/10.1097/PAS.0000000000002101CrossRefPubMed

76.

Argani P, Matoso A, Baraban EG, Epstein JI, Antonescu CR (2023) MED15::TFE3 renal cell carcinomas: report of two new cases and review of the literature confirming nearly universal multilocular cystic morphology. Int J Surg Pathol 31:409–414. https://doi.org/10.1177/10668969221143455CrossRefPubMedPubMedCentral

77.

Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, Gonzalez N, Illei PB, Ladanyi M, Griffin CA (2012) Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 36:1516–1526. https://doi.org/10.1097/PAS.0b013e3182613d8fCrossRefPubMedPubMedCentral

78.

Salles DC, Asrani K, Woo J, Vidotto T, Liu HB, Vidal I, Matoso A, Netto GJ, Argani P, Lotan TL (2022) GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms. J Pathol 257:158–171. https://doi.org/10.1002/path.5875CrossRefPubMedPubMedCentral

79.

Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA (2011) Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 24:430–442. https://doi.org/10.1038/modpathol.2010.213CrossRefPubMed

80.

Cajaiba MM, Jennings LJ, Rohan SM, Perez-Atayde AR, Marino-Enriquez A, Fletcher JA, Geller JI, Leuer KM, Bridge JA, Perlman EJ (2016) ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer 55:442–451. https://doi.org/10.1002/gcc.22346CrossRefPubMed

81.

Kuroda N, Trpkov K, Gao Y, Tretiakova M, Liu YJ, Ulamec M, Takeuchi K, Agaimy A, Przybycin C, Magi-Galluzzi C, Fushimi S, Kojima F, Sibony M, Hang JF, Pan CC, Yilmaz A, Siadat F, Sugawara E, Just PA, Ptakova N, Hes O (2020) ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol 33:2564–2579. https://doi.org/10.1038/s41379-020-0578-0CrossRefPubMed

82.

Wangsiricharoen S, Zhong M, Ranganathan S, Matoso A, Argani P (2021) ALK-rearranged renal cell carcinoma (RCC): a report of 2 cases and review of the literature emphasizing the distinction between VCL-ALK and Non-VCL-ALK RCC. Int J Surg Pathol 29:808–814. https://doi.org/10.1177/10668969211003660CrossRefPubMed

83.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R (2018) Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol 74:124–128. https://doi.org/10.1016/j.eururo.2018.03.032CrossRefPubMed

84.

Palsgrove DN, Li Y, Pratilas CA, Lin MT, Pallavajjalla A, Gocke C, De Marzo AM, Matoso A, Netto GJ, Epstein JI, Argani P (2018) Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol 42:1166–1181. https://doi.org/10.1097/PAS.0000000000001111CrossRefPubMedPubMedCentral

85.

Watanabe IC, Billis A, Guimaraes MS, Alvarenga M, de Matos AC, Cardinalli IA, Filippi RZ, de Castro MG, Suzigan S (2007) Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol 20:914–920. https://doi.org/10.1038/modpathol.3800934CrossRefPubMed

86.

Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH (2017) Genomic characterization of renal medullary carcinoma and treatment outcomes. Clin Genitourin Cancer 15:e987–e994. https://doi.org/10.1016/j.clgc.2017.04.012CrossRefPubMedPubMedCentral

87.

Argani P, Rose G, Matoso A, Gagan J, Palsgrove DN (2022) Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC) in a child with neurofibromatosis type 2 syndrome. Am J Surg Pathol 46:1595–1598. https://doi.org/10.1097/PAS.0000000000001942CrossRefPubMed

88.

Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN (2020) Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations. Am J Surg Pathol 44:901–916. https://doi.org/10.1097/PAS.0000000000001467CrossRefPubMedPubMedCentral

89.

Collins K, Hwang M, Antic T, Paintal A, Argani P, Matoso A, Gopinath A, Baskovich B, Mehra R, Williamson SR, Idrees MT, Barletta JA, Anderson WJ, Hirsch MS, Hornick JL, Acosta AM (2022) Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma. Histopathology 81:577–586. https://doi.org/10.1111/his.14731CrossRefPubMed

90.

Knezevich SR, Garnett MJ, Pysher TJ et al (1998) ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 58:5046–5048PubMed

Title: Paediatric renal tumours: an update on challenges and recent developments
Authors: Gino R. Somers
Aurore L’Herminé-Coulomb
Andres Matoso
Maureen J. O’Sullivan
Publication date: 09-01-2025
Publisher: Springer Berlin Heidelberg
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Nephroblastoma
Clear-Cell Sarcoma
Published in: Virchows Archiv
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-024-04017-x

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Paediatric renal tumours: an update on challenges and recent developments

Abstract

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content